Copyright © 1993 by the European Society of Cardiology.
© 1993 The Europen Society of Cardiology
Intravenous enoximone or dobutamine for severe heart failure after acute myocardial infarction: a randomized double-blind trial
Department of Cardiology, Royal Hallamshire Hospital Sheffield, U.K
Received 23 June 1992; revised 19 November 1992; .
Correspondence Dr K. S. Channer, Cardiology Department, Royal Hallamshire Hospital. Sheffield S10 2JF. U K.
Abstract
Intravenous infusions of enoximone or dobutamine were given, using a double dummy technique, in a randomized, double-blind study, to 18 patients with acute myocardial infarction who had persisting signs of left ventricular failure after treatment with intravenous diuretics. Blood pressure, heart rate and cardiac output, by transcutaneous Doppler aorto-velography, were measured and any arrhythmias recorded by Holier monitoring. Eight of the nine enoximone treated patients showedclinical improvement. One patient in the enoximone group failed to respond and subsequently died. Five of the nine dobutamine treated patients showed clinical improvement. The other four patients in the dobutamine group experienced tachyarrhythmias and were withdrawn from the study; one of these patients also deteriorated and died. There were no significant differences in systolic or diastolic blood pressure either within or between the two treatment groups during the study. Enoximone increased cardiac output by 32% (P=0.003), and dobutamine by 46% (P<0.001); there was no significant difference between groups. Dobutamine also significantly increased heart rate from a mean of 108 beats . min–1 to 117 beats. min–1 (P<0.001). There was no difference between the two groups in ventricular ectopic counts, but dobutamine produced significantly more runs of supraventricular and ventricular tachycardia (P=0.0003). Enoximone was better tolerated with fewer side-effects than dobutamine in doses which produced similar increases in cardiac output. In the setting of an acute myocardial infarction when inotropic therapy is indicated, enoximone is a better choice than dobutamine.
Key Words: Enoximone • dobutamine • acute myocardial infarction • congestive cardiac failure
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Gujic, C. Dreyfuss, J.-F. Argacha, S. Beloka, D. Adamopoulos, O. Xhaet, A. Pathak, and P. van de Borne Effects of enoximone on peripheral and central chemoreflex responses in humans Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H322 - H329. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. De Luca, W. S. Colucci, M. S. Nieminen, B. M. Massie, and M. Gheorghiade Evidence-based use of levosimendan in different clinical settings Eur. Heart J., August 2, 2006; 27(16): 1908 - 1920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Endorsed by the European Society of Intensive Care, Authors/Task Force Members, M. S. Nieminen, M. Bohm, M. R. Cowie, H. Drexler, G. S. Filippatos, G. Jondeau, Y. Hasin, J. Lopez-Sendon, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The Task Force on Acute Heart Failure of the European Society of Cardiology Eur. Heart J., February 2, 2005; 26(4): 384 - 416. [Full Text] [PDF]
|
|
|
|
|
|
V. S. Moiseyev, P. Poder, N. Andrejevs, M. Y. Ruda, A. P. Golikov, L. B. Lazebnik, Z. D. Kobalava, L. A. Lehtonen, T. Laine, M. S. Nieminen, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN) Eur. Heart J., September 2, 2002; 23(18): 1422 - 1432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Vroom Pharmacologic Management of Acute Heart Failure: A Review Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 1998; 2(3): 191 - 203. [Abstract] [PDF]
|
|